The objective is to allow Tetra Pak's customers or other producers of products to include The-A-complex as an ingredient, enabling potential future claims on benefits generated by the active complex. The processing technology and solutions will be sourced from Tetra Pak, the patent rights from Hamlet Pharma and the background scientific and small scale manufacturing know-how from Linnane Pharma, which will provide continued scientific support during the development process. The parties are further committed to exploring a mutual commercial agreement during the product validation process.

Importantly, HAMLET Pharma retains the patent rights to the "BAMLET complex", which is being developed separately for pharmaceutical use.

`'We are delighted to initiate this exciting development with the aim to commercialize an important part of our patent family'', says Hamlet Pharma

`'The-A-complex has important promise as an active component with the potential of a improving a range of food products,'' says Tetra Pak

This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 07-06-2021 15:48 CET.